» Articles » PMID: 38586475

Molecular and Functional Mapping of Plekhm1-Rab7 Interaction in Osteoclasts

Overview
Journal JBMR Plus
Date 2024 Apr 8
PMID 38586475
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in cause osteopetrosis in humans and rats. The germline and osteoclast conditional deletions of gene in mice lead to defective osteoclast bone resorption and increased trabecular bone mass without overt abnormalities in other organs. As an adaptor protein, pleckstrin homology and RUN domain containing M1 (PLEKHM1) interacts with the key lysosome regulator small GTPase RAB7 via its C-terminal RUBICON homologous (RH) domain. In this study, we have conducted a structural-functional study of the PLEKHM1 RH domain and RAB7 interaction in osteoclasts in vitro. The single mutations of the key residues in the Plekhm1 RH predicted from the crystal structure of the RUBICON RH domain and RAB7 interface failed to disrupt the Plekhm1-Rab7 binding, lysosome trafficking, and bone resorption. The compound alanine mutations at Y949-R954 and L1011-I1018 regions decreased Plekhm1 protein stability and Rab7-binding, respectively, thereby attenuated lysosome trafficking and bone resorption in osteoclasts. In contrast, the compound alanine mutations at R1060-Q1068 region were dispensable for Rab7-binding and Plekhm1 function in osteoclasts. These results indicate that the regions spanning Y949-R954 and L1011-I1018 of Plekhm1 RH domain are functionally important for Plekhm1 in osteoclasts and offer the therapeutic targets for blocking bone resorption in treatment of osteoporosis and other metabolic bone diseases.

Citing Articles

FAM98 Family Proteins Play Distinct Roles in Osteoclastogenesis and Bone Resorption.

Wang L, Minocha T, Das B, Kunika M, Kannan A, Gao L Biology (Basel). 2025; 14(1.

PMID: 39857276 PMC: 11762708. DOI: 10.3390/biology14010045.


Geranylgeranyl diphosphate synthase inhibition impairs osteoclast differentiation, morphology, and resorptive activity.

Muehlebach M, Haney S, Chhonker Y, Rashid M, Murry D, Talmon G JBMR Plus. 2024; 9(1):ziae133.

PMID: 39697524 PMC: 11653010. DOI: 10.1093/jbmrpl/ziae133.

References
1.
Toyomura T, Murata Y, Yamamoto A, Oka T, Sun-Wada G, Wada Y . From lysosomes to the plasma membrane: localization of vacuolar-type H+ -ATPase with the a3 isoform during osteoclast differentiation. J Biol Chem. 2003; 278(24):22023-30. DOI: 10.1074/jbc.M302436200. View

2.
Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

3.
Kanis J, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri N, Brandi M . Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int. 2017; 28(7):2023-2034. PMC: 5483332. DOI: 10.1007/s00198-017-4009-0. View

4.
Teitelbaum S . The osteoclast and its unique cytoskeleton. Ann N Y Acad Sci. 2011; 1240:14-7. DOI: 10.1111/j.1749-6632.2011.06283.x. View

5.
Takeshita S, Kaji K, Kudo A . Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res. 2000; 15(8):1477-88. DOI: 10.1359/jbmr.2000.15.8.1477. View